Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer

Small-cell neuroendocrine prostate cancer (SCNPC) exhibits an aggressive clinical course and incidence rates seem to be increasing following resistance to potent androgen receptor (AR) antagonists. Currently, treatment options are limited and few model systems are available to identify new approache...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2020-04, Vol.26 (7), p.1667-1677
Hauptverfasser:	Corella, Alexandra N, Cabiliza Ordonio, Ma Victoria Andrea, Coleman, Ilsa, Lucas, Jared M, Kaipainen, Arja, Nguyen, Holly M, Sondheim, Daniel, Brown, Lisha G, True, Lawrence D, Lee, John K, MacPherson, David, Nghiem, Paul, Gulati, Roman, Morrissey, Colm, Corey, Eva, Nelson, Peter S
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Receptor Antagonists - pharmacology Animals Antineoplastic Agents - pharmacology Apoptosis Carcinoma, Neuroendocrine - drug therapy Carcinoma, Neuroendocrine - genetics Carcinoma, Neuroendocrine - metabolism Carcinoma, Neuroendocrine - pathology Carcinoma, Small Cell - drug therapy Carcinoma, Small Cell - genetics Carcinoma, Small Cell - metabolism Carcinoma, Small Cell - pathology Cell Cycle Proteins - antagonists & inhibitors Cell Line, Tumor Gene Expression Regulation, Neoplastic Humans Male Mice Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - metabolism Prostatic Neoplasms, Castration-Resistant - pathology Protein-Tyrosine Kinases - antagonists & inhibitors Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors Signal Transduction Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!